Biogen Idec assume un ruolo significativo durante l'importante congresso di …ANSA.it… sua pipeline per terapie nelle fasi finali, fra cui: BG-12, interferone pegilato beta-1a e il processo daclizumab ad alto rendimento (DAC HYP) per la SM; oltr…
Auf der 64. AAN-Jahrestagung präsentierte Daten unterstreichen das Engagement …Live-PR.com (Pressemitteilung)… PEGyliertes Interferon Beta-1a und Daclizumab High-Yield Process (DAC HYP) für MS sowie Dexpramipexol, eine potenzielle Therapie für a…
New Data Presented at 64th AAN Annual Meeting Highlights Biogen Idec's …EON: Enhanced Online News (press release)… and FAMPYRA ® (prolonged-release fampridine tablets) – the company will present results from investigational trials of its lat…
New Data Presented at 64th AAN Annual Meeting Highlights Biogen Idec's …Financial Post… and FAMPYRA ® (prolonged-release fampridine tablets) – the company will present results from investigational trials of its late-stage pipeline, including…
New Data Presented at 64th AAN Annual Meeting Highlights Biogen Idec's …MarketWatch (press release)… and FAMPYRA(R) (prolonged-release fampridine tablets) — the company will present results from investigational trials of its late-stage pipelin…
OncLiveNovel Treatments for Chronic Lymphocytic LeukemiaOncLiveIn an effort to further improve efficacy and reduce toxicity, lenalidomide was explored in combination with the monoclonal antibody rituximab, reporting an ORR of 66% in relapsed CLL and 75…
OncLiveBeyond R-CHOP-21: What's New in Diffuse Large B-Cell LymphomaOncLiveThe current standard for patients with advanced diffuse large B-cell lymphoma (DLBCL) is R-CHOP-21 (21-day rituximab-cyclophosphamidedoxorubicin- vincristine-prednisone). Ho…
Abbott Laboratories Management Discusses Q1 2012 Results – Earnings Call …Seeking AlphaDaclizumab is a next-generation biologic in development for MS. Last year, Abbott and our partner company announced promising results from the first of 2 registrat…
Abbott Beats, Raises Outlook – Analyst BlogNASDAQAbbott Labs, along with partner Biogen ( BIIB ), is evaluating daclizumab in a phase III study for the treatment of relapsing-remitting multiple sclerosis ( RRMS ). Abbott Labs is also working on an inte…
Dividend.comAbbott Beats, Raises OutlookZacks.comAbbott Labs, along with partner Biogen (BIIB), is evaluating daclizumab in a phase III study for the treatment of relapsing-remitting multiple sclerosis (RRMS). Abbott Labs is also working on an intestin…